[1] Cummings JL. Alzheimer's disease. N Engl J Med 351: 56-67 (2004).
[2] Roberson ED, Mucke L. 100 years and counting: prospects for defeating Alzheimer's disease. Science 314: 781-784 (2006).
[3] Hardy J. A hundred years of Alzheimer's disease research. Neuron 52: 3-13 (2006).
[4] Sporn MB, Roberts AB, Goodman AB, Eds. The Retinoids. ACADEMIC PRESS, INC. 1(2): (1984).
[5] Dawson MI, Okamura WH, Eds. Chemistry and Biology of Synthetic Retinoids. CRC Press, Inc. (1990).
[6] Nau H, Blaner WS, Eds. Retinoids: The biochemical and molecular basis of vitamin A and retinoid action. Springer (1999).
[7] Kagechika H, Shudo K. Synthetic retinoids: recent developments concerning structure and clinical utility. J Med Chem 48: 5875- 5883 (2005).
[8] Kagechika H. Novel synthetic retinoids and separation of the pleiotropic retinoidal activities. Curr Med Chem 9: 591-608 (2002).
[9] Dawson MI. Synthetic retinoids and their nuclear receptors. Curr Med Chem Anticancer Agents 4: 199-230 (2004).
[10] de Lera AR, Bourguet W, Altucci L, Gronemeyer H. Design of selective nuclear receptor modulators: RAR and RXR as a case study. Nat Rev Drug Discov 6: 811-820 (2007).
[11] Napoli JL. Retinoic a
[12] Ross AC. Retinoid production and catabolism: role of diet in regu- lating retinol esterification and retinoic Acid oxidation. J Nutr 133: 291S-296S (2003).
[13] Blomhoff R, Blomhoff HK. Overview of retinoid metabolism and function. J Neurobiol 66: 606-630 (2006).
[14] Germain P, Chambon P, Eichele G, Evans RM, Lazar MA, Leid M, et al. International Union of Pharmacology. LX. Retinoic acid receptors. Pharmacol Rev 58: 712-725 (2006).
[15] Balmer JE, Blomhoff R. Gene expression regulation by retinoic acid. J Lipid Res 43: 1773-1808 (2002).
[16] Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 111: 2505-2515 (2008).
[17] Miwako I, Kagechika H. Tamibarotene. Drugs Today (Barc) 43: 563-568 (2007).
[18] Altucci L, Leibowitz MD, Ogilvie KM, de Lera AR, Gronemeyer H. RAR and RXR modulation in cancer and metabolic disease. Nat Rev Drug Discov 6: 793-810 (2007).
[19] Oikawa T, Okayasu I, Ashino H, Morita I, Murota S, Shudo K. Three novel synthetic retinoids, Re 80, Am 580 and Am 80, all ex- hibit anti-angiogenic activity in vivo. Eur J Pharmacol 249: 113- 116 (1993).
[20] Sardana K, Sehgal VN. Retinoids: fascinating up-and-coming scenario. J Dermatol 30: 355-380 (2003).
[21] Ishibashi Y. Clinical Effect of Am-80 Ointment on Psoriasis and Pustulosis Palmaris et Plantaris (Phase Study). RinshouIyaku 11: 747-759 (1995).
[22] Nickoloff BJ. Cracking the cytokine code in psoriasis. Nat Med 13: 242-244 (2007).
[23] Kuwabara K, Shudo K, Hori Y. Novel synthetic retinoic acid inhibits rat collagen arthritis and differentially affects serum immuno- globulin subclass levels. FEBS Lett 378: 153-156 (1996).
[24] Nagai H, Matsuura S, Bouda K, Takaoka Y, Wang T, Niwa S, et al. Effect of Am-80, a synthetic derivative of retinoid, on experimental arthritis in mice. Pharmacology 58: 101-112 (1999).
[25] Beehler BC, Brinckerhoff CE, Ostrowski J. Selective retinoic acid receptor ligands for rheumatoid arthritis. Curr Opin Investig Drugs 5: 1153-1157 (2004).
[26] Wiegman PJ, Barry WL, McPherson JA, McNamara CA, Gimple LW, Sanders JM, et al. All-trans-retinoic acid limits restenosis after 
[27] Fujiu K, Manabe I, Ishihara A, Oishi Y, Iwata H, Nishimura G, et al. Synthetic retinoid Am80 suppresses smooth muscle phenotypic modulation and in-stent neointima formation by inhibiting KLF5. Circ Res 97: 1132-1141 (2005).
[28] Sato M, Shudo K, Hiragun A. Functional studies of newly synthesized benzoic acid derivatives: identification of highly potent reti- noid-like activity. J Cell Physiol 135: 179-188 (1988).
[29] Massaro GD, Massaro D. Retinoic acid treatment abrogates elas- tase-induced pulmonary emphysema in rats. Nat Med 3: 675-677 (1997).
[30] Nishikiori N, Osanai M, Chiba H, Kojima T, Mitamura Y, Ohguro H, et al. Glial cell-derived cytokines attenuate the breakdown of vascular integrity in diabetic retinopathy. Diabetes 56: 1333-1340 (2007).
[31] Nishikiori N, Osanai M, Chiba H, Kojima T, Ohguro H, Sawada N. Inhibitory effects of retinoic acid receptor alpha stimulants on murine cataractogenesis through suppression of deregulated calpains. Invest Ophthalmol Vis Sci 48: 2224-2229 (2007).
[32] Miwako I, Shudo K. Oral administration of synthetic retinoid Am80 inhibits the development of type 1 diabetes in NOD mice. Biol Pharm Bull (in press).
[33] Osanai M, Nishikiori N, Murata M, Chiba H, Kojima T, Sawada N. Cellular retinoic acid bioavailability determines epithelial integrity: Role of retinoic acid receptor alpha agonists in colitis. Mol Pharmacol 71: 250-258 (2007).
[34] Phase Study of RR110 in Patients with Active Crohn's Disease [online]. Available from URL: 
[35] Standeven AM, Teng M, Chandraratna RA. Lack of involvement of retinoic acid receptor alpha in retinoid-induced skin irritation in hairless mice. Toxicol Lett 92: 231-240 (1997).
[36] Iulianella A, Lohnes D. Contribution of retinoic acid receptor gamma to retinoid-induced craniofacial and axial defects. Dev Dyn 209: 92-104 (1997).
[37] Look J, Landwehr J, Bauer F, Hoffmann AS, Bluethmann H, LeMotte P. Marked resistance of RAR gamma-deficient mice to the toxic effects of retinoic acid. Am J Physiol 269: E91-98 (1995).
[38] Reczek PR, Ostrowski J, Yu KL, Chen S, Hammer L, Roalsvig T, et al. Role of retinoic acid receptor gamma in the Rhino mouse and rabbit irritation models of retinoid activity. Skin Pharmacol 8: 292- 299 (1995).
[39] Seabrook GR, Ray WJ, Shearman M, Hutton M. Beyond amyloid: the next generation of Alzheimer's disease therapeutics. Mol Interv 7: 261-270 (2007).
[40] Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, et al. Inflammation and Alzheimer's disease. Neurobiol Aging 21: 383- 421 (2000).
[41] Britschgi M, Wyss-Coray T. Immune cells may fend off Alzheimer disease. Nat Med 13: 408-409 (2007).
[42] Maden M, Hind M. Retinoic acid, a regeneration-inducing mole- cule. Dev Dyn 226: 237-244 (2003).
[43] Maden M. Retinoic acid in the development, regeneration and maintenance of the nervous system. Nat Rev Neurosci 8: 755-765 (2007).
[44] Misner DL, Jacobs S, Shimizu Y, de Urquiza AM, Solomin L, Perlmann T, et al. Vitamin A deprivation results in reversible loss of hippocampal long-term synaptic plasticity. Proc Natl Acad Sci USA 98: 11714-11719 (2001).
[45] Mingaud F, Mormede C, Etchamendy N, Mons N, Niedergang B, Wietrzych M, et al. Retinoid hyposignaling contributes to aging- related decline in hippocampal function in short-term/working memory organization and long-term declarative memory encoding in mice. J Neurosci 28: 279-291 (2008).
[46] Goodman AB, Pardee AB. Evidence for defective retinoid transport and function in late onset Alzheimer's disease. Proc Natl Acad Sci USA 100: 2901-2905 (2003).
[47] Goodman AB. Retinoid receptors, transporters, and metabolizers as therapeutic targets in late onset Alzheimer disease. J Cell Physiol 209: 598-603 (2006).
[48] Weiner HL, Frenkel D. Immunology and immunotherapy of Alzheimer's disease. Nat Rev Immunol 6: 404-416 (2006).
[49] Prinzen C, Muller U, Endres K, Fahrenholz F, Postina R. Genomic structure and functional characterization of the human ADAM10 promoter. FASEB J 19: 1522-1524 (2005).
[50] Fahrenholz F, Postina R. Alpha-secretase activation--an approach to Alzheimer's disease therapy. Neurodegener Dis 3: 255-261 (2006).
[51] Fahrenholz F. Alpha-secretase as a therapeutic target. Curr Alzheimer Res 4: 412-417 (2007).
[52] Husson M, Enderlin V, Delacourte A, Ghenimi N, Alfos S, Pallet V, et al. Retinoic acid normalizes nuclear receptor mediated hypoexpression of proteins involved in beta-amyloid deposits in the cerebral cortex of vitamin A deprived rats. Neurobiol Dis 23: 1-10 (2006).
[53] Corcoran JP, So PL, Maden M. Disruption of the retinoid signalling pathway causes a deposition of amyloid beta in the adult rat brain. Eur J Neurosci 20: 896-902 (2004).
[54] El Khoury J, Toft M, Hickman SE, Means TK, Terada K, Geula C, et al. Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat Med 13: 432-438 (2007).
[55] Beers DR, Henkel JS, Zhao W, Wang J, Appel SH. CD4+ T cells support glial neuroprotection, slow disease progression, and modify glial morphology in an animal model of inherited ALS. Proc Natl Acad Sci USA 105: 15558-15563 (2008).
[56] Huang H, Patel DD, Manton KG. The immune system in aging: roles of cytokines, T cells and NK cells. Front Biosci 10: 192-215 (2005).
[57] Lucas SM, Rothwell NJ, Gibson RM. The role of inflammation in CNS injury and disease. Br J Pharmacol 147 (Suppl 1): S232-240 (2006).
[58] Weisman D, Hakimian E, Ho GJ. Interleukins, inflammation, and mechanisms of Alzheimer's disease. Vitam Horm 74: 505-530 (2006).
[59] Gadient RA, Otten U. Identification of interleukin-6 (IL-6)- expressing neurons in the cerebellum and hippocampus of normal adult rats. Neurosci Lett 182: 243-246 (1994).
[60] Tehranian R, Hasanvan H, Iverfeldt K, Post C, Schultzberg M. Early induction of interleukin-6 mRNA in the hippocampus and cortex of APPsw transgenic mice Tg2576. Neurosci Lett 301: 54- 58 (2001).
[61] Bhojak TJ, DeKosky ST, Ganguli M, Kamboh MI. Genetic polymorphisms in the cathespin D and interleukin-6 genes and the risk of Alzheimer's disease. Neurosci Lett 288: 21-24 (2000).
[62] Shibata N, Ohnuma T, Takahashi T, Baba H, Ishizuka T, Ohtsuka M, et al. Effect of IL-6 polymorphism on risk of Alzheimer disease: genotype-phenotype association study in Japanese cases. Am J Med Genet 114: 436-439 (2002).
[63] Zitnik RJ, Kotloff RM, Latifpour J, Zheng T, Whiting NL, Schwalb J, et al. Retinoic acid inhibition of IL-1-induced IL-6 production by human lung fibroblasts. J Immunol 152: 1419-1427 (1994).
[64] Kagechika H, Kawachi E, Fukasawa H, Saito G, Iwanami N, Umemiya H, et al. Inhibition of IL-1-induced IL-6 production by synthetic retinoids. Biochem Biophys Res Commun 231: 243-248 (1997).
[65] Dheen ST, Jun Y, Yan Z, Tay SS, Ling EA. Retinoic acid inhibits expression of TNF-alpha and iNOS in activated rat microglia. Glia 50: 21-31 (2005).
[66] Kaur C, Sivakumar V, Dheen ST, Ling EA. Insulin-like growth factor I and II expression and modulation in amoeboid microglial cells by lipopolysaccharide and retinoic acid. Neuroscience 138: 1233-1244 (2006).
[67] Schwab C, McGeer PL. Inflammatory aspects of Alzheimer disease and other neurodegenerative disorders. J Alzheimers Dis 13: 359- 369 (2008).
[68] Hyman BT, Smith C, Buldyrev I, Whelan C, Brown H, Tang MX, et al. Autoantibodies to amyloid-beta and Alzheimer's disease. Ann Neurol 49: 808-810 (2001).
[69] Troost D, van den Oord JJ, de Jong JM, Swaab DF. Lymphocytic infiltration in the spinal cord of patients with amyotrophic lateral sclerosis. Clin Neuropathol 8: 289-294 (1989).
[70] Kawamata T, Akiyama H, Yamada T, McGeer PL. Immunologic reactions in amyotrophic lateral sclerosis brain and spinal cord tissue. Am J Pathol 140: 691-707 (1992).
[71] Yoshino H. Immunological aspects of amyotrophic lateral sclerosis. Nippon Rinsho 52: 2984-2989 (1994).
[72] Hunot S, Hirsch EC. Neuroinflammatory processes in Parkinson's disease. Ann Neurol 53 (Suppl 3): S49-58; discussion S58-60 (2003).
[73] McGeachy MJ, Cua DJ. Th17 cell differentiation: the long and winding road. Immunity 28: 445-453 (2008).
[74] Ouyang W, Kolls JK, Zheng Y. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity 28: 454-467 (2008).
[75] Kebir H, Kreymborg K, Ifergan I, Dodelet-Devillers A, Cayrol R, Bernard M, et al. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat Med 13: 1173-1175 (2007).
[76] Wang W, Milani M, Ostlie N, Okita D, Agarwal RK, Caspi RR, et al. C57BL/6 mice genetically deficient in IL-12/IL-23 and IFN- gamma are susceptible to experimental autoimmune myasthenia gravis, suggesting a pathogenic role of non-Th1 cells. J Immunol 178: 7072-7080 (2007).
[77] Ifergan I, Kebir H, Bernard M, Wosik K, Dodelet-Devillers A, Cayrol R, et al. The blood-brain barrier induces differentiation of migrating monocytes into Th17-polarizing dendritic cells. Brain 131: 785-799 (2008).
[78] Zhong Z, Deane R, Ali Z, Parisi M, Shapovalov Y, O'Banion MK, et al. ALS-causing SOD1 mutants generate vascular changes prior to motor neuron degeneration. Nat Neurosci 11: 420-422 (2008).
[79] Racke MK, Burnett D, Pak SH, Albert PS, Cannella B, Raine CS, et al. Retinoid treatment of experimental allergic encephalomyelitis. IL-4 production correlates with improved disease course. J Immunol 154: 450-458 (1995).
[80] Wang T, Niwa S, Bouda K, Matsuura S, Homma T, Shudo K, et al. The effect of Am-80, one of retinoid derivatives on experimental allergic encephalomyelitis in rats. Life Sci 67: 1869-1879 (2000).
[81] Miyagawa N, Homma T, Kagechika H, Shudo K, Nagai H. Effect of synthetic retinoid, TAC-101, on experimental autoimmune disease. Pharmacology 67: 21-31 (2003).
[82] Iwata M, Eshima Y, Kagechika H. Retinoic acids exert direct effects on T cells to suppress Th1 development and enhance Th2 development via retinoic acid receptors. Int Immunol 15: 1017-1025 (2003).
[83] Fukasawa H, Kagechika H, Shudo K. Retinoid therapy for autoimmune diseases. Jpn J Clin Immunol 29: 114-126 (2006).
[84] Ivanov, II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, Lafaille JJ, et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 126: 1121-1133 (2006).
[85] Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 155: 1151-1164 (1995).
[86] Tang Q, Bluestone JA. The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. Nat Immunol 9: 239-244 (2008).
[87] Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 4: 330-336 (2003).
[88] Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 299: 1057- 1061 (2003).
[89] Viglietta V, Baecher-Allan C, Weiner HL, Hafler DA. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med 199: 971-979 (2004).
[90] Balandina A, Lecart S, Dartevelle P, Saoudi A, Berrih-Aknin S. Functional defect of regulatory CD4(+)CD25+ T cells in the thy- mus of patients with autoimmune myasthenia gravis. Blood 105: 735-741 (2005).
[91] Yamano Y, Takenouchi N, Li HC, Tomaru U, Yao K, Grant CW, et al. Virus-induced dysfunction of CD4+CD25+ T cells in patients with HTLV-I-associated neuroimmunological disease. J Clin Invest 115: 1361-1368 (2005).
[92] Rosenkranz D, Weyer S, Tolosa E, Gaenslen A, Berg D, Leyhe T, et al. Higher frequency of regulatory T cells in the elderly and increased suppressive activity in neurodegeneration. J Neuroimmunol 188: 117-127 (2007).
[93] Reynolds AD, Banerjee R, Liu J, Gendelman HE, Mosley RL. Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinson's disease. J Leukoc Biol 82: 1083-1094 (2007).
[94] Mucida D, Park Y, Kim G, Turovskaya O, Scott I, Kronenberg M, et al. Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid. Science 317: 256-260 (2007).
[95] Coombes JL, Siddiqui KR, Arancibia-Carcamo CV, Hall J, Sun CM, Belkaid Y, et al. A functionally specialized population of mu- cosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF- beta and retinoic acid-dependent mechanism. J Exp Med 204: 1757-1764 (2007).
[96] Kang SG, Lim HW, Andrisani OM, Broxmeyer HE, Kim CH. Vitamin A metabolites induce gut-homing Foxp3+ regulatory T cells. J Immunol 179: 3724-3733 (2007).
[97] Elias KM, Laurence A, Davidson TS, Stephens G, Kanno Y, Shevach EM, et al. Retinoic acid inhibits Th17 polarization and enhances Foxp3 expression through a Stat-3/Stat-5 independent signaling pathway. Blood 111: 1013-1020 (2008).
[98] Benson MJ, Pino-Lagos K, Rosemblatt M, Noelle RJ. All-trans retinoic acid mediates enhanced T reg cell growth, differentiation, and gut homing in the face of high levels of co-stimulation. J Exp Med 204: 1765-1774 (2007).
[99] Sun CM, Hall JA, Blank RB, Bouladoux N, Oukka M, Mora JR, et al. Small intestine lamina propria dendritic cells promote de novo generation of Foxp3 T reg cells via retinoic acid. J Exp Med 204: 1775-1785 (2007).
[100] Kim CH. Regulation of Foxp3 regulatory T cells and Th17 cells by retinoids. Clin Dev Immunol: 1-12 (2008).
[101] Takaki H, Ichiyama K, Koga K, Chinen T, Takaesu G, Sugiyama Y, et al. STAT6 Inhibits TGF-beta1-mediated Foxp3 induction through direct binding to the Foxp3 promoter, which is reverted by retinoic acid receptor. J Biol Chem 283: 14955-14962 (2008).
[102] Schambach F, Schupp M, Lazar MA, Reiner SL. Activation of retinoic acid receptor-alpha favours regulatory T cell induction at the expense of IL-17-secreting T helper cell differentiation. Eur J Immunol 37: 2396-2399 (2007).
[103] von Boehmer H. Oral tolerance: is it all retinoic acid? J Exp Med 204: 1737-1739 (2007).
[104] Strandberg TE, Pitkala KH, Linnavuori K, Tilvis RS. Cognitive impairment and infectious burden in the elderly. Arch Gerontol Geriatr Suppl: 419-423 (2004).
[105] D'Andrea MR. Add Alzheimer's disease to the list of autoimmune diseases. Med Hypotheses 64: 458-463 (2005).
[106] Perry VH, Cunningham C, Holmes C. Systemic infections and inflammation affect chronic neurodegeneration. Nat Rev Immunol 7: 161-167 (2007).
[107] Miklossy J. Chronic inflammation and amyloidogenesis in Alzheimer's disease -- role of spirochetes. J Alzheimers Dis 13: 381- 391 (2008).
[108] Itzhaki RF, Wozniak MA. Herpes simplex virus type 1 in Alzheimer's disease: the enemy within. J Alzheimers Dis 13: 393-405 (2008).
[109] Balin BJ, Little CS, Hammond CJ, Appelt DM, Whittum-Hudson JA, Gerard HC, et al. Chlamydophila pneumoniae and the etiology of late-onset Alzheimer's disease. J Alzheimers Dis 13: 371-380 (2008).
[110] Nicolson GL, Nasralla MY, Haier J, Pomfret J. High frequency of systemic mycoplasmal infections in Gulf War veterans and civil- ians with Amyotrophic Lateral Sclerosis (ALS). J Clin Neurosci 9: 525-529 (2002).
[111] Doty RL. The olfactory vector hypothesis of neurodegenerative disease: is it viable? Ann Neurol 63: 7-15 (2008).
[112] Ross GW, Petrovitch H, Abbott RD, Tanner CM, Popper J, Masaki K, et al. Association of olfactory dysfunction with risk for future Parkinson's disease. Ann Neurol 63: 167-173 (2008).
[113] Tabert MH, Liu X, Doty RL, Serby M, Zamora D, Pelton GH, et al. A 10-item smell identification scale related to risk for Alzheimer's disease. Ann Neurol 58: 155-160 (2005).
[114] Rawson NE, LaMantia AS. Once and again: retinoic acid signaling in the developing and regenerating olfactory pathway. J Neurobiol 66: 653-676 (2006).
[115] Rawson NE, LaMantia AS. A speculative essay on retinoic acid regulation of neural stem cells in the developing and aging olfactory system. Exp Gerontol 42: 46-53 (2007).
[116] Mey J, Morassutti DJ, Brook G, Liu RH, Zhang YP, Koopmans G, et al. Retinoic acid synthesis by a population of NG2-positive cells in the injured spinal cord. Eur J Neurosci 21: 1555-1568 (2005).
[117] Mey J. New therapeutic target for CNS injury? The role of retinoic acid signaling after nerve lesions. J Neurobiol 66: 757-779 (2006).
[118] Kern J, Schrage K, Koopmans GC, Joosten EA, McCaffery P, Mey J. Characterization of retinaldehyde dehydrogenase-2 induction in NG2-positive glia after spinal cord contusion injury. Int J Dev Neurosci 25: 7-16 (2007).
[119] Zhelyaznik N, Mey J. Regulation of retinoic acid receptors alpha, beta and retinoid X receptor alpha after sciatic nerve injury. Neuroscience 141: 1761-1774 (2006).
[120] Mey J, Schrage K, Wessels I, Vollpracht-Crijns I. Effects of inflammatory cytokines IL-1beta, IL-6, and TNFalpha on the intra- cellular localization of retinoid receptors in Schwann cells. Glia 55: 152-164 (2007).